This large pooled analysis included more than 1000 patients with type 2 diabetes mellitus (mean duration: ~5 years) treated for up to 1.4 years either with canakinumab, an IL-1β blocker or placebo. Here, IL1B is linked to type 2 diabetes mellitus.